Charles Zelen, DPM, FACFAS examines the use of purified reconstituted bilayer matrix (PRBM) as a treatment for chronic diabetic foot ulcers. Dr Charles Zelen reviews a recent clinical study and outline the clinical benefits of purified reconstituted bilayer matrix to improve wound healing outcomes.
Completion (Credits: 1.25) CME (Credits: 1) CEU (Credits: 1.25)
Post-Test
Survey
Certificate
Complete the 4 steps to earn your CE/CME credit:
This lecture has been approved for the PRESENT Residency Education Online Curriculum by the PRESENT Curriculum Committee.
Release Date: 03/23/2022 Expiration Date: 03/23/2023
PRESENT e-Learning Systems is approved by the Council on Podiatric Medical Education as a provider of continuing education in podiatric medicine. PRESENT e-Learning Systems has approved this activity for a maximum of 1 continuing education contact hours
Release Date: 03/23/2022 Expiration Date: 03/23/2023
NURSING: Nurse CE is provided for this program through collaboration between Present e-Learning Systems and AffinityCE. AffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC). This activity provides 1.25 contact hours of nurse CE credit.
Release Date: 03/23/2022 Expiration Date: 03/23/2023
Charles Zelen, DPM, FACFAS
ACFAS Fellowship Director
Professional Education and Research Institutr
Podiatry Section Chief
Dept of Orthopedics
HCA Lewis Gale Medical Center
Roanoke, VA
To view Lectures online, the following specs are required:
It is the policy of PRESENT e-Learning Systems and it's accreditors to insure balance, independence, objectivity and scientific rigor in all its individually sponsored or jointly sponsored educational programs. All faculty participating in any PRESENT e-Learning Systems sponsored programs are expected to disclose to the program audience any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the continuing education program. This pertains to relationships with pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the presentation topic. The intent of this policy is not to prevent a speaker with a potential conflict of interest from making a presentation. It is merely intended that any potential conflict should be identified openly so that the listeners may form their own judgments about the presentation with the full disclosure of the facts.
---Charles Zelen is the Medical Director of PERI and has received research funds from Geistlich Pharma AG to complete clinical studies.